On the stock market since 2025, it operates in the world of health and science. It has 4 employees. Now — the numbers.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
An investor who bought at the very peak is down 82% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Nothing in the current numbers stands out as a strong positive. That, by itself, is worth knowing.
Since the drop from its peak, buyer appetite hasn’t come back. Council score: 0/10.
On our five-subject report card, CBRA sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: CBRA is a high-risk stock — not yet profitable, and its future rides on its product catching on.